BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells This Information Is Current As of September 23, 2021

Total Page:16

File Type:pdf, Size:1020Kb

BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells This Information Is Current As of September 23, 2021 B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells This information is current as of September 23, 2021. Lai Guan Ng, Andrew P. R. Sutherland, Rebecca Newton, Fang Qian, Teresa G. Cachero, Martin L. Scott, Jeffrey S. Thompson, Julie Wheway, Tatyana Chtanova, Joanna Groom, Ian J. Sutton, Cynthia Xin, Stuart G. Tangye, Susan L. Kalled, Fabienne Mackay and Charles R. Mackay Downloaded from J Immunol 2004; 173:807-817; ; doi: 10.4049/jimmunol.173.2.807 http://www.jimmunol.org/content/173/2/807 http://www.jimmunol.org/ References This article cites 51 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/173/2/807.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 23, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells1 Lai Guan Ng,2* Andrew P. R. Sutherland,2*† Rebecca Newton,* Fang Qian,§ Teresa G. Cachero,§ Martin L. Scott,§ Jeffrey S. Thompson,§ Julie Wheway,* Tatyana Chtanova,*† Joanna Groom,* Ian J. Sutton,* Cynthia Xin,*† Stuart G. Tangye,‡ Susan L. Kalled,§ Fabienne Mackay,*† and Charles R. Mackay3*† BAFF (B cell-activating factor belonging to the TNF family) is a cell survival and maturation factor for B cells, and overproduction of BAFF is associated with systemic autoimmune disease. BAFF binds to three receptors, BAFF-R, transmembrane activator and Downloaded from calcium modulator and cyclophilin ligand interactor (TACI), and B cell maturation Ag (BCMA). Using specific mAbs, BAFF-R was found to be the predominant BAFF receptor expressed on peripheral B cells, in both humans and mice, and antagonist mAbs to BAFF-R blocked BAFF-mediated costimulation of anti-␮ responses. The other BAFF receptors showed a much more restricted expression pattern, suggestive of specialized roles. BCMA was expressed by germinal center B cells, while TACI was expressed predominantly by splenic transitional type 2 and marginal zone B cells, as well as activated B cells, but was notably absent from germinal center B cells. BAFF was also an effective costimulator for T cells, and this costimulation occurs entirely through http://www.jimmunol.org/ BAFF-R. BAFF-R, but not TACI or BCMA, was expressed on activated/memory subsets of T cells, and T cells from BAFF-R mutant A/WySnJ mice failed to respond to BAFF costimulation. Thus, BAFF-R is important not only for splenic B cell maturation, but is the major mediator of BAFF-dependent costimulatory responses in peripheral B and T cells. The Journal of Immunology, 2004, 173: 807–817. he B cell-activating factor from the TNF family (BAFF)4 and salivary glands of Sjo¨gren’s syndrome patients (7). These el- (also known as BLyS, TALL-1, zTNF-4, THANK, evated levels of BAFF in blood and tissues in human autoimmune TNFSF 13b), is emerging as an important regulator of B patients likely affect peripheral B cell survival as well as B cell T by guest on September 23, 2021 cell and T cell responses. BAFF was originally identified as a maturation and activation in the spleen, similar to effects of BAFF factor responsible for B cell survival and maturation (reviewed in in BAFF transgenic mice. Although high levels of BAFF have Refs. 1–3). BAFF was subsequently associated with autoimmune been associated mostly with autoimmune diseases, BAFF is likely disease, because transgenic mice overproducing BAFF produce important for normal immune responses to microbial challenge, by autoantibodies and develop diseases akin to human systemic lupus priming or enhancing T and B cell activity to facilitate clearance erythematosus and Sjo¨gren’s syndrome (4–8). In humans, high (11). The baff gene, located in humans on chromosome 13, has levels of BAFF are detectable in the blood of a proportion of been identified as a likely determinant for susceptibility to Ascaris patients with autoimmune rheumatic diseases, particularly sys- infection (12). temic lupus erythematosus and Sjo¨gren’s syndrome (7, 9, 10), and BAFF binds to several receptors. These include transmembrane BAFF is present at high levels in rheumatoid synovial fluid (9), activator and calcium modulator and cyclophilin ligand interactor (TACI), BAFF-R (BR3), and B cell maturation Ag (BCMA) (13– 17). Another TNF family member termed a proliferation-inducing *Arthritis and Asthma Research Program, The Garvan Institute of Medical Research, Sydney, †Cooperative Research Center for Asthma, Sydney, ‡Centenary Institute of ligand (APRIL) also binds to TACI and BCMA (14, 18). BAFF-R Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia; and appears to be particularly important for the regulation of B cell §Department of Research, Biogen Idec Inc., Cambridge, MA 02142 survival and maturation in the spleen, because A/WySnJ mice ex- Received for publication March 15, 2004. Accepted for publication May 14, 2004. pressing a defective BAFF-R have disrupted B cell maturation, The costs of publication of this article were defrayed in part by the payment of page similar to that seen in BAFF-deficient mice (17, 19). The BCMA charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. receptor appears not to play a role in B cell maturation but is 1 This work was supported by the Wellcome Trust, the Cooperative Research Center involved in plasma cell survival (20). In TACI-deficient mice, for Asthma, and the National Heath and Medical Research Council of Australia. there are increased B cell numbers, marked splenomegaly, and 2 L.G.N. and A.S. contributed equally to this work. mice develop autoimmune disorders (21). Antigenic challenge in 3 Address correspondence and reprint requests to Dr. Charles R. Mackay, Arthritis these mice results in enhanced Ab production (21). Because an and Inflammation Research Program, The Garvan Institute of Medical Research, 384 agonistic mAb to TACI inhibited B cell proliferation, signaling Victoria Street, Sydney, New South Wales 2010, Australia. E-mail address: [email protected] through TACI may in fact serve to down-regulate B cell activity (21). 4 Abbreviations used in this paper: BAFF, B cell-activating factor belonging to the TNF family; BCMA, B cell maturation Ag; h., human; hIgG, human IgG; GC, ger- BAFF and possibly APRIL also act on T cells. In vitro studies minal center; m., mouse; MZ, marginal zone; RBL, rat basophilic leukemia; TACI, of human T cells showed that BAFF provided a complete costimu- transmembrane activator and calcium modulator and cyclophilin ligand interactor; T1, transitional type 1; T2, transitional type 2; WT, wild type; APRIL, a proliferation- latory signal together with anti-TCR stimulation (22, 23). In mice, inducing ligand. a TACI-Fc fusion protein blocked activation of T cells in vitro, and Copyright © 2004 by The American Association of Immunologists, Inc. 0022-1767/04/$02.00 808 BAFF-R IS THE PRINCIPAL BAFF RECEPTOR FOR B AND T CELLS inhibited T cell priming in vivo (24). Also, treatment with hIgG (Novartis Pharmaceuticals, East Hanover, NJ), h.BCMA-Fc, or anti- TACI-Fc substantially inhibited inflammation, as well as bone and mouse BAFF-R (m.BAFF-R) mAbs (29). For Ag-specific T cell assays, cartilage destruction, in a mouse model of rheumatoid arthritis splenic T cells from DO11.10 TCR transgenic mice were purified by mag- netic separation, and 5 ϫ 104 cells/well were cultured with 1 ϫ 105 cells/ (24). T cells from transgenic mice that overexpressed human well of mitomycin C-inactivated APC, together with OVA peptide in 96- APRIL showed greatly enhanced survival in vitro and in vivo (25). well U-bottom plates. BAFF costimulation of T cells was performed by In autoimmune patients, inappropriate costimulation of T and B adding 4 ␮g/ml soluble BAFF or denatured BAFF to wells. For inhibition cells by BAFF may be an important component of disease patho- assays, cells were cultured with anti-m.BAFF-R mAbs (2 ␮g/ml), h.B- CMA-Fc, or hIgG (2 ␮g/ml). genesis. The receptor for BAFF on T cells is largely unknown, For anti-CD3 T cell proliferation assay, human T cells were activated although one study reported TACI expression on a subset of acti- using plate-bound anti-human CD3 mAb (mAb TR66), and mouse T cells vated T cells using a polyclonal Ab (26). Expression of BCMA and were activated with anti-mouse-CD3 mAb 145-2C11 (BD Pharmingen). BAFF-R is thought to be restricted to B cells (16, 17, 27, 28). Anti-CD3 mAb and BAFF were coated onto plates overnight in PBS at 4°C either separately or in combination, followed by two PBS washes. A total The critical functions of BAFF for B and T cell biology are ϩ of 2 ϫ 106 PBMC (human) or CD3 (human or mouse) cells/ml were facilitated by the regulated expression of BAFF receptors.
Recommended publications
  • CD137 Microbead Kit CD137 Microbead + Cells
    CD137 MicroBead Kit human Order no. 130-093-476 Contents 1.2 Background information 1. Description The activation-induced antigen CD137 (4-1BB) is a 30 kDa glycoprotein of the tumor necrosis factor (TNF) receptor 1.1 Principle of the MACS® Separation + + superfamily. It is mainly expressed on activated CD4 and CD8 1.2 Background information T cells, activated B cells, and natural killer cells, but can also be 1.3 Applications found on resting monocytes and dendritic cells. As a costimulatory molecule, CD137 is involved in the activation 1.4 Reagent and instrument requirements and survival of CD4, CD8, and NK cells. Its engagement enhances 2. Protocol expansion of T cells and activates them to secrete cytokines. CD137 has been described to be a suitable marker for antigen- 2.1 Sample preparation specific activation of human CD8+ T cells, as CD137 is not expressed 2.2 Magnetic labeling on resting CD8+ T cells and its expression is reliably induced after 2.3 Magnetic separation 24 hours of stimulation.¹,² 3. Example of a separation using the CD137 MicroBead Kit 1.3 Applications 4. References ● Enrichment of CD137+ T cells for phenotypical and functional 5. Appendix characterization. ● Enrichment of activated antigen-specific T cells after antigen- Warnings specific stimulation. Reagents contain sodium azide. Under acidic conditions sodium 1.4 Reagent and instrument requirements azide yields hydrazoic acid, which is extremely toxic. Azide ● compounds should be diluted with running water before discarding. Buffer: Prepare a solution containing phosphate-buffered These precautions are recommended to avoid deposits in plumbing saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), where explosive conditions may develop.
    [Show full text]
  • Cells Promote Survival and Differentiation of B Up-Regulated In
    Expression of the Adaptor Protein Hematopoietic Src Homology 2 is Up-Regulated in Response to Stimuli That Promote Survival and Differentiation of B This information is current as Cells of September 28, 2021. Brantley R. Herrin and Louis B. Justement J Immunol 2006; 176:4163-4172; ; doi: 10.4049/jimmunol.176.7.4163 http://www.jimmunol.org/content/176/7/4163 Downloaded from References This article cites 48 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/176/7/4163.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Expression of the Adaptor Protein Hematopoietic Src Homology 2 is Up-Regulated in Response to Stimuli That Promote Survival and Differentiation of B Cells Brantley R. Herrin and Louis B. Justement1 Analysis of hematopoietic Src homology 2 (HSH2) protein expression in mouse immune cells demonstrated that it is expressed at low levels in resting B cells but not T cells or macrophages.
    [Show full text]
  • Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
    [Show full text]
  • TACI:Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 39, No. 3, 343-352, June 2007 TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice 1,2,3 2 Eun-Yi Moon and Sook-Kyung Ryu the percentage of non-lymphoid cells and no changes were detected in lymphoid cell population. 1 Department of Bioscience and Biotechnology Hypodiploid cell formation in BALF was decreased Sejong University by OVA-challenge but it was recovered by TACI:Fc Seoul 143-747, Korea treatment. Collectively, data suggest that asthmatic 2 Laboratory of Human Genomics symptom could be alleviated by scavenging BAFF Korea Research Institute of Bioscience and Biotechnology (KRIBB) and then BAFF could be a novel target for the Daejeon 305-806, Korea develpoment of anti-asthmatic agents. 3 Corresponding author: Tel, 82-2-3408-3768; Fax, 82-2-466-8768; E-mail, [email protected] Keywords: asthma; B-cell activating factor; ovalbu- and [email protected] min; transmembrane activator and CAML interactor protein Accepted 28 March 2007 Introduction Abbreviations: BAFF, B cell activating factor belonging to TNF- family; BALF, bronchoalveolar lavage fluid; OVA, ovalbumin; PAS, Mature B cell generation and maintenance are regu- periodic acid-Schiff; Prx, peroxiredoxin; TACI, transmembrane lated by B-cell activating factor (BAFF). BAFF is pro- activator and calcium modulator and cyclophilin ligand interactor duced by macrophages or dendritic cells upon stim- ulation with LPS or IFN- . BAFF belongs to the TNF family. Its biological role is mediated by the specific Abstract receptors, B-cell maturation antigen (BCMA), trans- membrane activator and calcium modulator and cy- Asthma was induced by the sensitization and chal- clophilin ligand interactor (TACI) and BAFF receptor, lenge with ovalbumin (OVA) in mice.
    [Show full text]
  • CD134 (OX40) Antibodies, Human for Research Use Only
    CD134 (OX40) antibodies, human For research use only One test corresponds to labeling of up to 107 cells in a total volume of 100 µL. Product Content Order no. CD134 (OX40)­VioBright FITC for 30 tests 130­109­664 CD134 (OX40)­VioBright FITC for 100 tests 130­109­605 CD134 (OX40)­PE for 30 tests 130­109­660 CD134 (OX40)­PE for 100 tests 130­109­601 CD134 (OX40)­APC for 30 tests 130­109­661 CD134 (OX40)­APC for 100 tests 130­109­602 CD134 (OX40)­PE­Vio770 for 30 tests 130­109­662 CD134 (OX40)­PE­Vio770 for 100 tests 130­109­603 CD134 (OX40)­APC­Vio770 for 30 tests 130­109­663 CD134 (OX40)­APC­Vio770 for 100 tests 130­109­604 CD134 (OX40)­Biotin for 30 tests 130­109­659 CD134 (OX40)­Biotin for 100 tests 130­109­600 Warnings Reagents contain sodium azide. Under acidic conditions sodium azide yields hydrazoic acid, which is extremely toxic. Azide compounds should be diluted with running water before discarding. These precautions are recommended to avoid deposits in plumbing where explosive conditions may develop. Technical data and background information Antigen CD134 (OX40) Clone REA621 Isotype recombinant human IgG1 Isotype control REA Control (S) antibodies Alternative names of antigen OX­40, OX40 Molecular mass of antigen [kDa] 27 Distribution of antigen B cells, endothelial cells, fibroblasts, lymphocytes, T cells Product format Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide. Fixation Cells should be stained prior to fixation, if formaldehyde is used as a fixative. Storage Store protected from light at 2–8 °C.
    [Show full text]
  • The Thrombopoietin Receptor : Revisiting the Master Regulator of Platelet Production
    This is a repository copy of The thrombopoietin receptor : revisiting the master regulator of platelet production. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/175234/ Version: Published Version Article: Hitchcock, Ian S orcid.org/0000-0001-7170-6703, Hafer, Maximillian, Sangkhae, Veena et al. (1 more author) (2021) The thrombopoietin receptor : revisiting the master regulator of platelet production. Platelets. pp. 1-9. ISSN 0953-7104 https://doi.org/10.1080/09537104.2021.1925102 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Platelets ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iplt20 The thrombopoietin receptor: revisiting the master regulator of platelet production Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker To cite this article: Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker (2021): The thrombopoietin receptor: revisiting the master regulator of platelet production, Platelets, DOI: 10.1080/09537104.2021.1925102 To link to this article: https://doi.org/10.1080/09537104.2021.1925102 © 2021 The Author(s).
    [Show full text]
  • Role of ADAM10 and ADAM17 in Regulating CD137 Function
    International Journal of Molecular Sciences Article Role of ADAM10 and ADAM17 in Regulating CD137 Function Jana Seidel 1, Sinje Leitzke 1, Björn Ahrens 1, Maria Sperrhacke 1, Sucharit Bhakdi 2 and Karina Reiss 1,* 1 Department of Dermatology, University of Kiel, 24105 Kiel, Germany; [email protected] (J.S.); [email protected] (S.L.); [email protected] (B.A.); [email protected] (M.S.) 2 Independent Researcher, 24105 Kiel, Germany; [email protected] * Correspondence: [email protected] Abstract: Human CD137 (4-1BB), a member of the TNF receptor family, and its ligand CD137L (4-1BBL), are expressed on immune cells and tumor cells. CD137/CD137L interaction mediates bidirectional cellular responses of potential relevance in inflammatory diseases, autoimmunity and oncology. A soluble form of CD137 exists, elevated levels of which have been reported in patients with rheumatoid arthritis and various malignancies. Soluble CD137 (sCD137) is considered to represent a splice variant of CD137. In this report, however, evidence is presented that A Disintegrin and Metalloproteinase (ADAM)10 and potentially also ADAM17 are centrally involved in its generation. Release of sCD137 by transfected cell lines and primary T cells was uniformly inhibitable by ADAM10 inhibition. The shedding function of ADAM10 can be blocked through inhibition of its interaction with surface exposed phosphatidylserine (PS), and this effectively inhibited sCD137 generation. The phospholipid scramblase Anoctamin-6 (ANO6) traffics PS to the outer membrane and thus modifies ADAM10 function. Overexpression of ANO6 increased stimulated shedding, and hyperactive ANO6 led to maximal constitutive shedding of CD137.
    [Show full text]
  • Successful Treatment of CD30+Lymphomatoid Papulosis
    ooggeenneessii iinn ss && rrcc aa MM CC uu tt ff aa Journal ofJournal of oo gg ll ee ee aa aa nn nn nn nn ee ee rr rr ss ss uu uu ii ii Watabe et al., J Carcinog Mutagen 2014, 5:3 ss ss oo oo JJ JJ ISSN: 2157-2518 CarCarcinogenesiscinogenesis & Mutagenesis DOI: 10.4172/2157-2518.1000174 Case Report Open Access Successful Treatment of CD30+Lymphomatoid Papulosis using a 308-nm Excimer Light Akiko Watabe, Taku Fujimura*, Sadanori Furudate and Setsuya Aiba Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan *Corresponding author: Taku Fujimura, Department of Dermatology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, 980-8574, Japan, Tel:+81 (22) 717-7271; Fax: +81 (22) 717-7361; E-mail: [email protected] Received date: Mar 11, 2014, Accepted date: May 03, 2014, Published date: May 07, 2014 Copyright: © 2013 Watabe A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract We describe a 61-year-old Japanese patient with Lymphomatoid papulosis (LYP) successfully archived complete remission, using a 308-nm Excimer light. Interestingly, immunohistochemical staining revealed that CD30+ anaplastic tumor cells were surrounded by CD163+ macrophages and CCL18 producing cells, both of which were reported to correlate with the prognosis of CTCL. Our present study sheds light on the possible pathogenesis of LYP and the possibility of a 308-nm Excimer light phototherapy for LYP.
    [Show full text]
  • Downloaded and Further Processed with the R Programming Language ( and Bioconductor ( Software
    bioRxiv preprint doi: https://doi.org/10.1101/801530; this version posted October 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. An integrated multi-omic single cell atlas to redefine human B cell memory David R. Glass,1,2,5 Albert G. Tsai,2,5 John Paul Oliveria,2,3 Felix J. Hartmann,2 Samuel C. Kimmey,2,4 Ariel A. Calderon,1,2 Luciene Borges,2 Sean C. Bendall1,2,6,* 1Immunology Graduate Program, Stanford University, Stanford, CA, 94305, USA 2Department of Pathology, Stanford University, Stanford, CA, 94305, USA 3Department of Medicine, Division of Respirology, McMaster University, Hamilton, ON, L8S4K1, Canada 4Department of Developmental Biology, Stanford, University, Stanford CA, 94305, USA 5Co-first author 6Lead Author *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/801530; this version posted October 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Abstract: To evaluate the impact of heterogeneous B cells in health and disease, comprehensive profiling is needed at a single cell resolution. We developed a highly- multiplexed screen to quantify the co-expression of 351 surface molecules on low numbers of primary cells. We identified dozens of differentially expressed molecules and aligned their variance with B cell isotype usage, metabolism, biosynthesis activity, and signaling response.
    [Show full text]
  • Targeting Costimulatory Molecules in Autoimmune Disease
    Targeting costimulatory molecules in autoimmune disease Natalie M. Edner1, Gianluca Carlesso2, James S. Rush3 and Lucy S.K. Walker1 1Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF 2Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 3Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland *Correspondence: Professor Lucy S.K. Walker. Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. Email: [email protected]. 1 Abstract Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, and efforts have focused in particular on the CD28 family members CTLA-4 and PD-1. In autoimmunity, these same pathways can be targeted to opposite effect, to curb the over- exuberant immune response. The CTLA-4 checkpoint serves as an exemplar, whereby CTLA-4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of soluble CTLA-4 in autoimmunity. Here we review the targeting of costimulatory molecules in autoimmune disease, focusing in particular on the CD28 family and TNFR family members. We present the state-of-the-art in costimulatory blockade approaches, including rational combinations of immune inhibitory agents, and discuss the future opportunities and challenges in this field. 2 The risk of autoimmune disease is an inescapable consequence of the manner in which the adaptive immune system operates. To ensure effective immunity against a diverse array of unknown pathogens, antigen recognition systems based on random gene rearrangement and mutagenesis have evolved to anticipate the antigenic universe.
    [Show full text]
  • Adipocytes As Immune Cells: Differential Expression of TWEAK
    Adipocytes as Immune Cells: Differential Expression of TWEAK, BAFF, and APRIL and Their Receptors (Fn14, BAFF-R, TACI, and BCMA) at Different Stages of Normal This information is current as and Pathological Adipose Tissue of September 26, 2021. Development Vassilia-Ismini Alexaki, George Notas, Vassiliki Pelekanou, Marilena Kampa, Maria Valkanou, Panayiotis Theodoropoulos, Efstathios N. Stathopoulos, Andreas Tsapis Downloaded from and Elias Castanas J Immunol published online 14 October 2009 http://www.jimmunol.org/content/early/2009/10/14/jimmuno l.0901186 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2009/10/13/jimmunol.090118 Material 6.DC1 Why The JI? Submit online. by guest on September 26, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 14, 2009, doi:10.4049/jimmunol.0901186 The Journal of Immunology Adipocytes as Immune Cells: Differential Expression of TWEAK, BAFF, and APRIL and Their Receptors (Fn14, BAFF-R, TACI, and BCMA) at Different Stages of Normal and Pathological Adipose Tissue Development1 Vassilia-Ismini Alexaki,* George Notas,* Vassiliki Pelekanou,2* Marilena Kampa,* Maria Valkanou,* Panayiotis Theodoropoulos,† Efstathios N.
    [Show full text]
  • FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
    Published OnlineFirst April 28, 2020; DOI: 10.1158/1078-0432.CCR-19-2958 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models A C Matthew A. Lakins, Alexander Koers, Raffaella Giambalvo, Jose Munoz-Olaya, Robert Hughes, Emma Goodman, Sylwia Marshall, Francisca Wollerton, Sarah Batey, Daniel Gliddon, Mihriban Tuna, and Neil Brewis ABSTRACT ◥ Purpose: With the increased prevalence in checkpoint therapy Results: We demonstrated simultaneous binding of CD137 þ resistance, there remains a significant unmet need for additional andPD-L1andshowedpotentT-cell activation across CD8 therapies for patients with relapsing or refractory cancer. We have T-cell activation assays in a PD-L1–dependent manner with a developed FS222, a bispecific tetravalent antibody targeting CD137 CD137/PD-L1 bispecific antibody, FS222. FS222 also activated and PD-L1, to induce T-cell activation to eradicate tumors without T cells in a human primary mixed lymphocyte reaction assay, with the current toxicity and efficacy limitations seen in the clinic. greater potency than the monospecific mAb combination. FS222 Experimental Design: A bispecific antibody (FS222) was devel- showed no signs of liver toxicity up to 30 mg/kg in a non-human oped by engineering CD137 antigen–binding sites into the Fc region primate dose-range finding study. A surrogate molecule caused of a PD-L1 IgG1 mAb. T-cell activation by FS222 was investigated significant tumor growth inhibition and survival benefit, concom- þ using multiple in vitro assays. The antitumor efficacy, survival itant with CD8 T-cell activation, in CT26 and MC38 syngeneic benefit, pharmacodynamics, and liver pharmacology of a murine mouse tumor models.
    [Show full text]